M-J. Ahn | Researchain

Archive Network Publication Hotspot Collaboration

Network

Latest external collaboration on country level. Dive into details by clicking on the dots.

Explore More

Hotspot

Dive into the research topics where M-J. Ahn is active.

Explore More

Publication

Featured researches published by M-J. Ahn.

Annals of Oncology | 2017

LBA45_PRPembrolizumab (pembro) vs standard of care (SOC) for recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): Phase 3 KEYNOTE-040 trial

Ezra E.W. Cohen; Kevin J. Harrington; C. Le Tourneau; Jose Dinis; L. Licitra; M-J. Ahn; Ainara Soria; J-P Machiels; Nicolas Mach; Ranee Mehra; Barbara Burtness; Y. Wang; A.J. Tuozzo; Ramona F. Swaby; Denis Soulières

Annals of Oncology | 2016

Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC after progression on 1st line gefitinib (IMPRESS study): Final overall survival (OS) analysis

J-C. Soria; S. Kim; Y-L. Wu; Kazuhiko Nakagawa; J-J. Yang; M-J. Ahn; J. Wang; J.C-H. Yang; Y-S Lu; S. Atagi; S. Ponce Aix; Yuri Rukazenkov; R. Taylor; T. Mok

Annals of Oncology | 2016

Phase 1/2 study of the safety and clinical activity of durvalumab in patients with non-small cell lung cancer (NSCLC)

S.J. Antonia; J.R. Brahmer; S. Khleif; A.S. Balmanoukian; S-H.I. Ou; M. Gutierrez; D-W. Kim; S. Kim; M-J. Ahn; J. Leach; R. Jamal; D. Jaeger; G. Jerusalem; X. Jin; A. Gupta; J. Antal; N.H. Segal

Annals of Oncology | 2017

1348POverall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies

Tetsuya Mitsudomi; M-J. Ahn; Lyudmila Bazhenova; Fiona Blackhall; T. Hida; M. Majem Tarruella; S.L. Vowler; G. Laus; Pasi A. Jänne; J.C-H. Yang

Annals of Oncology | 2016

Assessment of health-related quality of life (HRQoL) in KEYNOTE-010: A phase 2/3 study of pembrolizumab vs docetaxel in patients with previously treated advanced NSCLC

Fabrice Barlesi; Edward B. Garon; D-W. Kim; E. Felip; J. Han; J-H. Kim; M-J. Ahn; Mary J. Fidler; Matthew A. Gubens; G. Castro; V. Surmont; Q. Li; A. C. Deitz; Gregory M. Lubiniecki; Roy S. Herbst

Annals of Oncology | 2017

1141PDCA-170, a first in class oral small molecule dual inhibitor of immune checkpoints PD-L1 and VISTA, demonstrates tumor growth inhibition in pre-clinical models and promotes T cell activation in Phase 1 study

J. Powderly; Manish R. Patel; J. Jack Lee; J. Brody; Funda Meric-Bernstam; Erika Paige Hamilton; S. Ponce Aix; J. Garcia-Corbacho; Y-J Bang; M-J. Ahn; S. Y. Rha; K-P. Kim; M. Gil Martin; Huaibin Wang; A. Lazorchak; T. Wyant; A. Ma; S. Agarwal; David Tuck; Adil Daud

Annals of Oncology | 2016

Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001, -010, and -024

C. Aggarwal; D. Rodriguez Abreu; E. Felip; Enric Carcereny; M. Gottfried; T. Wehler; M-J. Ahn; M. Dolled-Filhart; J. Zhang; Yue Shentu; R. Rangwala; B. Piperdi; Paul Baas

Annals of Oncology | 2016

Pembrolizumab (pembro) vs docetaxel (doce) for previously treated, PD-L1–expressing NSCLC: Updated outcomes of KEYNOTE-010

Roy S. Herbst; Paul Baas; D-W. Kim; E. Felip; Jose Luis Perez-Gracia; J. Han; Julian R. Molina; J-H. Kim; C. Dubos Arvis; M-J. Ahn; Margarita Majem; Mary J. Fidler; G. de Castro; Marcelo Garrido; Yue Shentu; Gregory M. Lubiniecki; Edward B. Garon

Annals of Oncology | 2016

Ceritinib in ROS1-rearranged non-small-cell lung cancer: a Korean nationwide phase II study

Si-Keun Lim; Byoung Chul Cho; H.R. Kim; Js Lee; K-E Lee; Y-G. Lee; Y.J. Min; Eun Kyung Cho; S-S. Lee; B. T. Kim; M.Y. Choi; H.S. Shim; Jooyoung Chung; Y.L. Choi; Miyoung Lee; M-J. Ahn

Annals of Oncology | 2017

LBA19A phase 1b study of RXDX-105, a VEGFR-sparing potent RET inhibitor, in RETi-naïve patients with RET fusion-positive NSCLC

A.E. Drilon; S. Liu; R. Doebele; C. Rodriguez; M. Fakih; K.L. Reckamp; Lyudmila Bazhenova; Byoung Chul Cho; E. Kowack; J. Oliver; P. Multani; M-J. Ahn

Explore More